Gilead Sciences

This study tests whether the antiviral drug tenofovir can safely lower hepatitis B virus levels in children aged 2 to 12 with chronic infection. Participants receive either the drug or a placebo for 48 weeks. The goal is to see if the drug can control the virus and improve liver …

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that doesn't have specific genetic changes. About 193 participants will receive the…

This study tests whether a combination of two drugs (sacituzumab govitecan and pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that has a specific marker (PD-L1). About 443 participants who have not …

This study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or returned and cannot be cur…

This study tests a new long-acting drug called lenacapavir for people with HIV that has become resistant to many current medications. The goal is to see if adding this drug to their existing treatment can lower the amount of virus in their blood. The study involves 72 adults and …

This study tests whether a new once-weekly pill (GS-1720 plus GS-4182) can keep HIV under control as well as the daily pill Biktarvy. About 675 adults with already-suppressed HIV will take either the weekly combo or continue Biktarvy. The goal is to see if the weekly option is sa…

This study tests whether sacituzumab govitecan, a targeted antibody carrying a chemotherapy drug, works better than the standard chemo docetaxel for people with advanced non-small cell lung cancer that has spread. About 600 participants whose cancer worsened after platinum chemo …

This study tests a new drug called emvistegrast (GS-1427) for people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. About 228 adults will receive either the drug or a placebo to see if it helps reduce symptoms like bleedin…

This early-phase study tests a new drug called GS-4528, given alone or with an immunotherapy drug, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 182 participants will take part…

This study tests whether combining immunotherapy drugs can shrink tumors in people with advanced non-small cell lung cancer. About 400 adults with stage IV cancer will receive these combinations. The main goals are to see how many patients respond and to check for side effects.

This study tests if switching to a new two-drug combination pill (bictegravir/lenacapavir) works as well as staying on the standard three-drug pill (Biktarvy) for people with HIV-1 who already have the virus under control. About 577 participants will be randomly assigned to one o…

This study tests if people with HIV-1 who are already well-controlled on a daily pill can switch to a once-weekly tablet (islatravir/lenacapavir) without losing viral suppression. About 609 participants will be randomly assigned to either the weekly regimen or continue their curr…

This study tests a drug called sacituzumab govitecan against standard chemotherapy in 640 people with endometrial cancer that has returned or persisted after platinum-based chemo and immunotherapy. The goal is to see if the new drug can slow cancer growth or extend survival. Part…

This study tests if people with HIV-1 who are already well-controlled on daily medication can safely switch to a once-weekly pill (islatravir/lenacapavir). About 600 participants will either switch to the weekly pill or stay on their current daily regimen. The main goal is to see…

This study looks at whether switching to a new two-drug combination (bictegravir/lenacapavir) is safe and effective for people with HIV-1 who are already on stable but complex treatment. About 689 participants will be randomly assigned to either the new combo or their current the…

This early-stage study tests a new drug called GS-0272 in about 55 adults with rheumatoid arthritis. The main goal is to check if the drug is safe and how the body processes it at different doses. Participants will receive either the study drug or a placebo, and researchers will …

This study tests how well the drug sacituzumab govitecan works in people with advanced solid tumors that have not responded to other treatments. About 53 adults with certain types of esophageal or stomach cancer will receive the drug. The main goal is to see if tumors shrink or d…

This study compares a new drug, sacituzumab govitecan, to standard chemotherapy in people with a common type of advanced breast cancer (HR+/HER2-) that has not responded to at least two prior chemotherapies. The goal is to see if the new drug can slow cancer growth or improve sur…

This study tests the long-term safety of a drug called seladelpar in people with primary biliary cholangitis (PBC), a chronic liver disease. About 340 adults who previously took seladelpar in another PBC study will continue taking it and be monitored for side effects. The goal is…

This study tests whether a once-weekly oral combination of two drugs (islatravir and lenacapavir) can keep HIV under control in people whose virus is already suppressed. About 142 adults with HIV who have been on a standard daily pill for at least 24 weeks will take the weekly re…

This study tests a new long-acting HIV treatment that combines two lab-made antibodies (teropavimab and zinlirvimab) with the drug lenacapavir, given as injections every 6 months. It involves 83 adults whose HIV is already well-controlled by daily pills. The goal is to see if swi…

This study is testing a new once-daily pill (Bictegravir/Emtricitabine/Tenofovir Alafenamide) for HIV-1 in adolescents and children. The goal is to see how the drug works in the body, confirm the right dose, and check its safety. About 177 participants aged 2 to 17 who already ha…

This study follows 170 people with chronic hepatitis D who are taking the medication bulevirtide. Researchers want to see how well the drug works over the long term and what side effects may occur. The main focus is on serious liver problems like liver failure, liver cancer, or n…

This study tests a drug called sacituzumab govitecan in people with a common type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy. The goal is to see if it can keep the cancer from growing longer than current standard chemotherapies. About 654…

This study looks at how safe and effective certain HIV medicines are for children from 4 weeks to under 18 years old. The drugs are meant to keep the virus under control, not cure it. About 133 kids will take part to help find the right doses and check for side effects.

This early-phase study tests a new drug called GS-9911, given alone or with an immunotherapy drug, in 45 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. This is a first step to see if the a…

This study compares a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) plus chemotherapy against the standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has not been treated before. About 1,021 pa…

This early-phase study tests an experimental drug called GS-9716 in about 145 people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects when given alone or with other cancer drugs. Partici…

This study tests a drug called sacituzumab govitecan in 80 Chinese patients with metastatic triple-negative breast cancer who have already tried at least two other treatments. The main goal is to see how many patients' tumors shrink or disappear. This is an advanced cancer that i…

This study tests a drug called sacituzumab govitecan in 227 people whose solid tumors have spread to other parts of the body. The goal is to see if the drug can shrink or control the cancer. Participants must have already tried standard treatments like chemotherapy or immunothera…

This study compares a targeted drug, sacituzumab govitecan, against standard chemotherapy in people with advanced triple-negative breast cancer that does not express PD-L1 (a protein that makes immunotherapy work). About 623 participants will receive either the new drug or their …

This study tested two ways to prevent HIV in over 5,000 adolescent girls and young women at risk. One group received a long-acting shot (lenacapavir) every 6 months, and another took a daily pill (F/TAF). The goal was to see how well each method works compared to the expected inf…

This study tested a new daily pill (F/TAF) to prevent HIV in over 5,000 men and transgender women who have sex with men and are at high risk of HIV. Participants took either the new pill or an older one (F/TDF) for at least 48 weeks. The goal was to see how many got HIV during th…

This study tested whether the drug obeldesivir could safely prevent filovirus disease (like Ebola) in people who were recently exposed. It was designed for high-risk individuals, but the study was withdrawn before enrolling anyone. No results are available.

This study tests a new HIV medicine (B/F/TAF) in full-term newborns who were exposed to HIV but are not infected. The goal is to see if the drug is safe and how the body processes it. Sixteen babies will receive the medicine shortly after birth to help prevent HIV infection.

This study looks at a new long-acting shot called lenacapavir, given every 6 months, to prevent HIV in people who inject drugs. About 181 participants in the US will receive either the shot or daily pills. The goal is to see how well the drug works in the body and if it is safe.

This study tests a new HIV prevention method: a shot called lenacapavir given only twice a year. It compares how well people stick with this shot versus taking a daily pill (Truvada). The study involves 268 people at higher risk of HIV, including men who have sex with men, transg…

This study looks at a new HIV prevention shot (lenacapavir) given just twice a year, compared to a daily pill, in 253 cisgender women in the US. The goal is to see how the shot moves through the body, if it's safe, and if women find it acceptable. This could make HIV prevention m…

This study tests a long-acting shot called lenacapavir, given every 6 months, to prevent HIV infection in people at high risk. Over 3,200 participants who have sex with male partners and do not use condoms received the shot or a daily pill. The goal is to see if the shot is safer…